Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript
Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript
Artivion Q1 Earnings Call Highlights
Artivion NYSE: AORT executives said the company delivered double-digit revenue and adjusted EBITDA growth in the first quarter of 2026, while also lowering its full-year revenue outlook due primarily to softer stent graft trends and timing around U.S. AMDS account stocking.
Artivion (AORT) Q1 Earnings and Revenues Surpass Estimates
Artivion (AORT) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.06 per share a year ago.
Artivion Secures FDA Approval for NEXUS Aortic Arch System
AORT jumps after FDA approves NEXUS Aortic Arch System, unlocking a potential Endospan acquisition and advancing minimally invasive care for high-risk patients.
Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock?
Artivion (AORT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Artivion, Inc. (AORT) Q4 2025 Earnings Call Transcript
Artivion, Inc. (AORT) Q4 2025 Earnings Call Transcript
Artivion (AORT) Q4 Earnings Surpass Estimates
Artivion (AORT) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to break-even earnings per share a year ago.
Artivion Continues Building Toward Bigger And Better Things
Artivion continues to outperform the med-tech sector, driven by strong execution in stent grafts and On-X valve businesses. Recent clinical updates for the AMDS prosthesis reinforce its safety and efficacy, supporting further adoption and de-risking full commercialization. I expect double-digit long-term revenue growth, expanding EBITDA margins, and a fair value in the high-$50s, justifying a bullish stance.
Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?
Here is how Artivion (AORT) and Pacific Biosciences of California (PACB) have performed compared to their sector so far this year.
Artivion, Inc. (AORT) Q3 2025 Earnings Call Transcript
Artivion, Inc. ( AORT ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Pat MacKin Lance Berry - EVP, COO, CFO & Treasurer Conference Call Participants Lynn Lewis - Gilmartin Group LLC John McAulay - Stifel, Nicolaus & Company, Incorporated, Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Suraj Kalia - Oppenheimer & Co. Inc., Research Division Joseph Conway - Needham & Company, LLC, Research Division Daniel Stauder - Citizens JMP Securities, LLC, Research Division Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Good afternoon, and welcome to the Artivion Third Quarter 2025 Earnings Call. [Operator Instructions].
Artivion (AORT) Tops Q3 Earnings and Revenue Estimates
Artivion (AORT) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.12 per share a year ago.
Artivion, Inc. (AORT) Q2 2025 Earnings Call Transcript
Artivion, Inc. (NYSE:AORT ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Lance A. Berry - Executive VP of Finance & CFO Pat MacKin - Corporate Participant Conference Call Participants Daniel Walker Stauder - Citizens JMP Securities, LLC, Research Division Destiny Alexandra Hance Buch - Ladenburg Thalmann & Co. Inc., Research Division John Glenn McAulay - Stifel, Nicolaus & Company, Incorporated, Research Division William John Plovanic - Canaccord Genuity Corp., Research Division Dorothy Morgan - Gilmartin Group LLC Operator Good day, ladies and gentlemen, and welcome to the Artivion Second Quarter 2025 Earnings Call.
